ACTR-17. EVOPHOSPHAMIDE (TH-302) FOR RECURRENT GBM FOLLOWING BEVACIZUMAB FAILURE, FINAL RESULTS OF A MULTICENTER PHASE II STUDY

INTRODUCTION: Evophosphamide is a hypoxia-activated prodrug that, when activated in hypoxic conditions, (<0.5% O2), releases the bis-alkylating agent bromo-isophosphoramide mustard (Br-IPM). Our prior phase 1 study in recurrent GBM (rGBM) with dose expansion showed preliminary activity with a 24%...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Neuro Oncol
Autores principales: Brenner, Andrew J, Reardon, David, Wen, Patrick, Huang, Shiliang, Fox, Peter, Muzi, Mark, Lee, Eudocia
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2018
Materias:
Abstracts
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6216171/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.051
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares